MedTrace Logo

Endometrial Polyps Regression With Progesterone Therapy

NCT03309709 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-01-15

No results posted yet for this study

Summary

This prospective randomized study will compare the regression rates of women managed with watch-and-wait approach and of those treated with 3 cycles of luteal 25mg subcutaneous progesterone from 18 to 25 days of menstrual cycle

Conditions

  • Endometrial Polyp

Interventions

DRUG

subcutaneous progesterone

25mg daily for 7 days

Sponsors & Collaborators

  • University Magna Graecia

    lead OTHER

Principal Investigators

  • Roberta Venturella, MD · Magna Graecia University of Catanzaro

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-08
Primary Completion
2019-10-30
Completion
2019-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309709 on ClinicalTrials.gov